Publications by authors named "P Leia Nghiemphu"
A radio-pathomic machine learning (ML) model has been developed to estimate tumor cell density, cytoplasm density (Cyt) and extracellular fluid density (ECF) from multimodal MR images and autopsy pathology. In this multicenter study, we implemented this model to test its ability to predict survival in patients with recurrent glioblastoma (rGBM) treated with chemotherapy. Pre- and post-contrast T-weighted, FLAIR and ADC images were used to generate radio-pathomic maps for 51 patients with longitudinal pre- and post-treatment scans.
View Article and Find Full Text PDFPurpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults.
Methods: ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles.
Article Synopsis
- This study evaluates the effectiveness of normalized apparent diffusion coefficient (nADC) versus percentage T2-FLAIR mismatch-volume (%T2FM-volume) in distinguishing IDH-mutant astrocytoma from other glioma types.* -
- The analysis involved 105 non-enhancing gliomas, utilizing T2-FLAIR digital subtraction maps to identify tumor subregions, yielding results that showed nADC was significantly higher in IDH-mutant astrocytomas compared to other glioma subtypes.* -
- Overall, nADC was found to be a more reliable classifier than %T2FM-volume, demonstrating higher sensitivity and specificity in identifying IDH-mutant astrocytomas, while survival analysis results indicated a trend
Article Synopsis
- Background: -related schwannomatosis (formerly neurofibromatosis type 2) is a progressive tumor syndrome characterized by various tumors including vestibular and nonvestibular schwannomas, meningiomas, and ependymomas, with no approved treatments available.
- Methods: A phase 2 trial was conducted involving patients aged 12 and older with -SWN, treating them daily with 180 mg of oral brigatinib, and evaluating tumor response and safety through a central review committee.
- Results: Out of 40 patients, radiographic response rates were 10% for target tumors and 23% for all tumors, with improvements notably in meningiomas
Typical longitudinal radiographic assessment of brain tumors relies on side-by-side qualitative visualization of serial magnetic resonance images (MRIs) aided by quantitative measurements of tumor size. However, when assessing slowly growing tumors and/or complex tumors, side-by-side visualization and quantification may be difficult or unreliable. Whole-brain, patient-specific "digital flipbooks" of longitudinal scans are a potential method to augment radiographic side-by-side reads in clinical settings by enhancing the visual perception of changes in tumor size, mass effect, and infiltration across multiple slices over time.
View Article and Find Full Text PDF